Are you finding it hard to get your news story published in the mainstream media?
Look no further - share it FREE on NewsBoosters and reach the people directly
Centralizing Socially Relevant News To Boost Its Visibility Your News, Our Outreach....     
  
View 921

Source ForPressRelease.com

Aducanumab is a new drug for treatment of Alzheimer's disease approved by FDA on 7 June 2021. It is a monoclonal antibody, one of the first disease modifying agents, that target the basic pathology or the hypothesised cause for Alzheimer's disease.



It has got conditional FDA's accelerated approval that means the company has to conduct another, may be so called phase IV clinical trial to verify the benefits. FDA can withdraw the drug if the trial fails to show clinical benefit.



For clinician like me, it is an exciting news of a drug approved for Alzheimer's disease after nearly two decades, and first one targeting the pathology. I would eagerly wait for results of next suggested trial as FDA put it, before discussing the option with the clients. I would also be concerned over the pricing as it is anticipated to cost $56000 per year for package of recommended 14 treatments.



It is given Intravenous infusion approximately 4 weeks apart.



Dizziness, confusion, headache & also hypersensitivity reactions are reported as adverse effects of this drug.



As per reports, this Monoclonal antibody targets and clears out the amyloid beta plaques & reduces it's deposition, thus reducing the toxicity to the nerve cells. The studies found apparently significant reduction in the amount of Amyloid plaques compared to controls based on the PET Imaging studies. When the plaque deposits reduce, toxicity reduces, and so the cells do not degenerate & therefore available to function. Therefore one may expect reduced or less likely of the progression of the illness if it is successful in significant reduction in plaque deposits.


 
 
 

Target Communities :

Why it is important:

What is the end objective of the news?:

What needs to be done to meet the objective?:

 
 
 
 
 
 
 
 
 
 
Latest Newsboosters News